HOWL

Company Overview — What Does Werewolf Therapeutics, Inc. Do?

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Werewolf Therapeutics, Inc. (HOWL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Daniel J. Hicklin and employs approximately 40 people. With a market capitalization of $47M, HOWL is one of the notable companies in the Healthcare sector.

Werewolf Therapeutics, Inc. (HOWL) Stock Rating — Reduce (April 2026)

As of April 2026, Werewolf Therapeutics, Inc. receives a Reduce rating with a composite score of 24.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.HOWL ranks #3,548 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Werewolf Therapeutics, Inc. ranks #563 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HOWL Stock Price and 52-Week Range

Werewolf Therapeutics, Inc. (HOWL) currently trades at $0.88. The stock lost $0.02 (1.9%) in the most recent trading session. The 52-week high for HOWL is $2.38, which means the stock is currently trading -63.0% from its annual peak. The 52-week low is $0.53, putting the stock 66.2% above its annual trough. Recent trading volume was 41K shares, suggesting relatively thin trading activity.

Is HOWL Overvalued or Undervalued? — Valuation Analysis

Werewolf Therapeutics, Inc. (HOWL) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.96x, versus the sector average of 2.75x.

At current multiples, Werewolf Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Werewolf Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Werewolf Therapeutics, Inc. (HOWL) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -278.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -99.6% versus the sector average of -33.1%.

Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HOWL Debt, Balance Sheet, and Financial Health

Werewolf Therapeutics, Inc. has a debt-to-equity ratio of 129.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.62x, suggesting adequate working capital coverage. Total debt on the balance sheet is $32M. Cash and equivalents stand at $66M.

HOWL has a beta of 2.04, meaning it is more volatile than the broader market — a $10,000 investment in HOWL would be expected to move 104.3% more than the S&P 500 on any given day. The stability factor score for Werewolf Therapeutics, Inc. is 16/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Werewolf Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Werewolf Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.32. Net income for the quarter was $-69M. Operating income came in at $-68M.

In FY 2025, Werewolf Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.32. Net income for the quarter was $-61M. Operating income came in at $-61M.

In Q3 2025, Werewolf Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.36. Net income for the quarter was $-16M. Operating income came in at $-16M.

In Q2 2025, Werewolf Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.40. Net income for the quarter was $-18M. Operating income came in at $-18M.

Over the past 8 quarters, Werewolf Therapeutics, Inc. has experienced revenue contraction from $1M to $0. Investors analyzing HOWL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HOWL Dividend Yield and Income Analysis

Werewolf Therapeutics, Inc. (HOWL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

HOWL Momentum and Technical Analysis Profile

Werewolf Therapeutics, Inc. (HOWL) has a momentum factor score of 27/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 40/100 reflects moderate short selling activity.

HOWL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Werewolf Therapeutics, Inc. (HOWL) ranks #563 out of 838 stocks based on the Blank Capital composite score. This places HOWL in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing HOWL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HOWL vs S&P 500 (SPY) comparison to assess how Werewolf Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

HOWL Next Earnings Date

No upcoming earnings date has been announced for Werewolf Therapeutics, Inc. (HOWL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HOWL? — Investment Thesis Summary

The quantitative profile for Werewolf Therapeutics, Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Momentum is weak at 27/100, a headwind for near-term performance. High volatility (stability score 16/100) increases portfolio risk.

In summary, Werewolf Therapeutics, Inc. (HOWL) earns a Reduce rating with a composite score of 24.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HOWL stock.

Related Resources for HOWL Investors

Explore more research and tools: HOWL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HOWL head-to-head with peers: HOWL vs AZN, HOWL vs SLGL, HOWL vs VMD.